

Houston VACCINESHEEFA Biotech Start-Up company space

The area where our VACCINESHEEFA Start-Up company Accelerator and Biotech Incubator JLAB Space in Houston

In the area where VACCINESHEEFA R&D company operates in the over 34,000 square feet of common, wet lab, and office space, Houston site boasts the largest Biotechnic R&D footprint in the US.

The JLABS portfolio is as diverse as US, with companies hailing from five countries, and seven states. The JLABS portfolio spans the breadth of life sciences with companies focused on oncology, biotechnology, vaccines, pharmaceuticals, and medical devices, turning Houston into the true third coast of innovation.



To help cooperated medical device companies and partners in the TMCx cohort and Bio Design program innovate faster, we recently renovated a ~1,000-square foot concept lab into a full-scale prototyping space, which includes specialized software, electronics testing and assembly equipment, rapid fabrication and 3D printing capabilities.

JLABS is already linking regional entrepreneurs to the global subject matter experts internally at Innovation, including opportunities to discuss funding, access third-party services, attend educational events and meet with R&D experts from our medical device, consumer healthcare and pharmaceutical teams. Like all of our cooperation sites, JLABS has an open innovation, no-strings attached approach.



JLABS Innovation seeks to find the best science and technology, no matter where it is located, to solve the greatest unmet medical and healthcare needs of our time. As one of the top global biotechnology clusters, and home to the **Texas Medical Center**, the largest medical center in the world, JLABS plays a pivotal role in Houston's flourishing life science hub. The JLABS model enables talented scientists in the region to take their innovations to the next level, furthering our goal of helping entrepreneurs advance science with the potential to become transformational solutions for patients.

The world needs to have technologies, facilities, investments and investors that can produce hundreds of millions of doses of the vaccines that are cheaper and can be maintained at room temperature.

We look forward to working with you, and together, improving healthcare and our innovation ecosystem and biotechnic vaccines around the world.

